Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

fuerst73 Jul. 29 at 8:09 AM

$CABA First signs showing up in pre-market today. But the real signal? My RSNHBP tool spotted the silent base weeks ago — now we’re watching if this one wakes up. 📈 This is how I plan breakouts early. 🔍 RSNHBP – Silent base → First action 👉 https://fuerst73.gumroad.com/l/wzirnn #CABA #BreakoutWatch #TradingView #RSNHBP #Premarket

0 · Reply

fuerst73 Jul. 28 at 7:24 PM

$CABA The overall market’s been soft — but $CABA is quietly holding strong. Silent Base → First Action (with RSNHBP) is starting to stack signals. Not jumping in yet, but I’ve got it on high alert. This type of relative strength often leads the next leg. 👀 📌 fuerst73.gumroad.com/l/wzirnn #CABA #RSNHBP #setupwatch #tradingview #relativeStrength

0 · Reply

fuerst73 Jul. 28 at 6:18 PM

👀 $CABA is on my watchlist. Spotted it early thanks to my custom TradingView indicator – showing a clean Silent Base forming. Let’s see if it wakes up 🔎 📌 fuerst73.gumroad.com/l/wzirnn #CABA #tradingview #watchlist #swingtrading

0 · Reply

Stockholm111 Jul. 28 at 2:09 PM

$CABA Only thing that brings this up big is a big pharna partnership or buyout. Carl June is on the board and yet it is a $1.70 stock. Go figure

1 · Reply

Moonman321 Jul. 27 at 7:22 PM

$CABA anybody holding over 30,000 shares here This is going to be epic

6 · Reply

Moonman321 Jul. 27 at 5:28 AM

$CABA $PGEN $VTYX $QBTS

0 · Reply

LifeisaMeme Jul. 26 at 8:16 PM

$CABA Im about to spill beans. My top 3 Biotech stocks are VTYX, CABA and possibly PGEN. I will let Moonman321 judge. Take it away Moonman.

1 · Reply

Athenis Jul. 26 at 6:19 PM

$CABA Lonza 🔥 = CABA stability 🧬 Strong half-year figures from the GMP partner strengthen confidence in Rese‑Cel scaling

0 · Reply

Moonman321 Jul. 26 at 3:23 AM

$CABA we’re about to get busy People buy stocks when they’re going up They should be loading the boat as this drops Once this takes off, we will never see these numbers again Rate cuts on their way !! 🐑 🐻 are toast. They will be covering next week 😂 FOOLS 🐷 🐑 🐻

0 · Reply

Moonman321 Jul. 25 at 7:48 PM

$CABA $50,000 Investment can bring you 500,000 within a year on a stock like this Who wouldn’t take the chance on that The Penny flippers and the 🐻 who post all the time on here Get your position now and sit on it The fed will be cutting. This is going to be an epic couple years.

0 · Reply

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 6 weeks ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 6 weeks ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 6 weeks ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 2 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 2 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 4 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 4 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 5 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 5 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 5 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 5 months ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 6 months ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 7 months ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 9 months ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 10 months ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 28, 2024, 8:00 AM EDT - 11 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 1 year ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 1 year ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 1 year ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 1 year ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 1 year ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 1 year ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 2 years ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

May 31, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 22, 2023, 4:30 PM EDT - 2 years ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023, 8:20 AM EDT - 2 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CYH EXAS MRNA NVAX ORGO PFE RARE

May 17, 2023, 10:16 PM EDT - 2 years ago

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023, 4:01 PM EDT - 2 years ago

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 16, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 11, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 4:35 PM EDT - 2 years ago

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

Apr 27, 2023, 4:49 PM EDT - 2 years ago

Cabaletta Bio: Speculative Biotech With Opportunity

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

fuerst73 Jul. 29 at 8:09 AM

0 · Reply

fuerst73 Jul. 28 at 7:24 PM

0 · Reply

fuerst73 Jul. 28 at 6:18 PM

0 · Reply

Stockholm111 Jul. 28 at 2:09 PM

$CABA Only thing that brings this up big is a big pharna partnership or buyout. Carl June is on the board and yet it is a $1.70 stock. Go figure

1 · Reply

Moonman321 Jul. 27 at 7:22 PM

$CABA anybody holding over 30,000 shares here This is going to be epic

6 · Reply

Moonman321 Jul. 27 at 5:28 AM

$CABA $PGEN $VTYX $QBTS

0 · Reply

LifeisaMeme Jul. 26 at 8:16 PM

$CABA Im about to spill beans. My top 3 Biotech stocks are VTYX, CABA and possibly PGEN. I will let Moonman321 judge. Take it away Moonman.

1 · Reply

Athenis Jul. 26 at 6:19 PM

$CABA Lonza 🔥 = CABA stability 🧬 Strong half-year figures from the GMP partner strengthen confidence in Rese‑Cel scaling

0 · Reply

Moonman321 Jul. 26 at 3:23 AM

0 · Reply

Moonman321 Jul. 25 at 7:48 PM

0 · Reply

MobyDick2324 Jul. 25 at 6:36 PM

$CABA Saw this on latest presentation for short term catalysts:

0 · Reply

ProfitMaker4 Jul. 25 at 12:43 PM

$CABA Continuing to accumulate at these levels. Solid financials and a great portfolio. I am bullish on the LT with this company with both huge upside on trials results as well as a strong buyout candidate result dependant. In my view, anything sub $2 is a gift and continuing to avg down.

2 · Reply

LifeisaMeme Jul. 24 at 2:18 PM

$CABA POV: You can't stop winning in Biotech's while 99% of people lose because they can't identify the good ones but you have a natural instinct.

0 · Reply

Moonman321 Jul. 24 at 4:07 AM

$CABA Loading more tomorrow can’t resist 10 X ❤️ The fed will be cutting the tariffs will be resolved, and we will rock it Maybe we’ll get a small dip sinking 30 G more

0 · Reply

Ghjuuff Jul. 23 at 10:40 PM

$SAVA $SAVA $CABA $OPEN up to million$

1 · Reply

vu_jade Jul. 23 at 5:09 PM

$CABA gets some 🥬

0 · Reply

Moonman321 Jul. 23 at 3:54 PM

$QBTS $CABA $CABA taking off 30 K will be Mucho grande in a year Price target 25 Currently 1.66 lol If you get a dip, buy it EXPi This will be an incredible second half of the year and ongoing Long and 💪🏻 💥

0 · Reply

WillyRo57 Jul. 23 at 3:37 PM

$CABA off to a good start

0 · Reply

deson Jul. 23 at 2:36 PM

$CABA Go, baby, go....

0 · Reply

Kawasaki1 Jul. 23 at 2:29 AM

$CABA She gonna fly soon

0 · Reply

Adriens Jul. 23 at 12:07 AM

$CABA

0 · Reply

LifeisaMeme Jul. 22 at 4:14 PM

$CABA This is a very good buy. Im waiting for NVNO to skyrocket then im moving here. There is tons of reasons which I will list later why you should own this.

0 · Reply

Market Cap	84.23M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	846,500
Avg Vol	2,529,006
Day's Range	N/A - N/A
Shares Out	50.74M
Stochastic %K	69%
Beta	2.70
Analysts	Strong Sell
Price Target	$15.67